Arcadia Biosciences appoints Stan Jacot as CEO; grants inducement option for 316K shares

Arcadia Biosciences, Inc.

Stan Jacot named President and CEO effective Feb 2, 2022; previous president of Jane's Dough Foods (6-year tenure with double-digit CAGR).
Annual base salary $350,000, target bonus 50% of base; inducement stock option for 316,108 shares at $0.91 (vests over four years).
Kevin Comcowich steps down as interim CEO but remains Chairman of the Board.
Severance agreement provides 9 months base salary continuation (non-CIC) or 12 months with full equity vesting acceleration after change of control.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

Kevin Comcowich

Interim President and Chief Executive Officer

RKDA · Arcadia Biosciences, Inc.

Effective: 2022-02-02
Successor: Stanley Jacot, Jr.
Filed: February 7, 2022, 6:59 PM ET

In connection with Mr. Jacot’s appointment, Kevin Comcowich resigned as interim president and chief executive officer of the Company, effective February 2, 2022.

Appointed

Stanley Jacot, Jr.

President and Chief Executive Officer

RKDA · Arcadia Biosciences, Inc.

Effective: 2022-02-02
Filed: February 7, 2022, 6:59 PM ET

On February 2, 2022, (the “Effective Date”), Arcadia Biosciences, Inc. (“the Company”) hired Stanley Jacot, Jr. as the new president and chief executive officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin Comcowich resigned as Interim President and Chief Executive Officer at Arcadia Biosciences, Inc..

Action: resigned
Role: Interim President and Chief Executive Officer

Exact text from the filing

In connection with Mr. Jacot’s appointment, Kevin Comcowich resigned as interim president and chief executive officer of the Company, effective February 2, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stanley Jacot, Jr. was appointed as President and Chief Executive Officer at Arcadia Biosciences, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On February 2, 2022, (the “Effective Date”), Arcadia Biosciences, Inc. (“the Company”) hired Stanley Jacot, Jr. as the new president and chief executive officer of the Company.

View on SEC.gov

Arcadia Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-000832

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.